Relapse patterns and clinical outcomes after BCMA-directed CAR-T therapy in multiple myeloma: a real-world single-center study
Despite deep remissions achieved with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (MM), most patients eventually relapse. Although extramedullary disease (EMD) has been associated with poor prognosis after BCMA-directed CAR-T the...